心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Circulation：NLRP3炎症小体可促进房颤的发生发展

2018-11-17 MedSci MedSci原创

NLRP3炎症小体房颤心肌细胞
关注

心房颤动(AF)常与炎症反应增强相关。NLRP3(NACHT、 LRR和保护PYD结构域的蛋白质3)炎症体介导免疫细胞的caspase-1激活和白介素-1β释放，但尚不明确其在心肌细胞(CMs)中的具体作用。现研究人员对CM NLRP3炎症小体在AF中的作用进行研究。通过免疫印迹法检测阵发性AF或长期持续性（慢性）AF患者的心房全组织溶解物和CMs的NLRP3炎症小体的激活。为明确NLRP3的CM

心房颤动(AF)常与炎症反应增强相关。NLRP3(NACHT、 LRR和保护PYD结构域的蛋白质3)炎症体介导免疫细胞的caspase-1激活和白介素-1β释放，但尚不明确其在心肌细胞(CMs)中的具体作用。现研究人员对CM NLRP3炎症小体在AF中的作用进行研究。

通过免疫印迹法检测阵发性AF或长期持续性（慢性）AF患者的心房全组织溶解物和CMs的NLRP3炎症小体的激活。为明确NLRP3的CM特异性激活是否可有效促进AF，研究人员建立CM特异性表达持续性活化的NLRP3的小鼠模型（CM-KI）。

在阵发性房颤和慢性房颤患者心房中，NLRP3炎性小体活性增强。CM-KI小鼠出现自发性早发型房颤和诱导性房颤，并可被NLRP3炎性小体特异性抑制剂MCC950减弱。此外，CM-KI小鼠还出现异位电活动、肌浆网Ca2+释放异常、心房有效不应期缩短、心房肥大。腺相关病毒亚型-9介导的CM特异性敲除Nlrp3可抑制CM-KI小鼠的AF发展。最后，抑制Nlrp3可阻止CREM转基因小鼠（一种公认的自发性AF的小鼠模型）AF的发生。

本研究揭示了CM NLRP3炎症小体信号的新的病理生理作用，并与AF病理相联系，同时表明抑制NLRP3或可作为治疗AF的新方法。


原始出处：

Chunxia Yao，et al.Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. 24 Jul 2018. Circulation. 2018；138：2227–2242

本文系梅斯医学（MedSci）原创编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030742, encodeId=ac012030e4266, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Mon Mar 11 02:54:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690690, encodeId=29ff169069076, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Wed Nov 28 03:54:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407751, encodeId=1f11140e75172, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538784, encodeId=2f581538e84bc, content=<a href='/topic/show?id=93341286ee6' target=_blank style='color:#2F92EE;'>#NLRP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12867, encryptionId=93341286ee6, topicName=NLRP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=981f13051678, createdName=vera_1207, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2019-03-11 wgsun

    #发生发展#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2030742, encodeId=ac012030e4266, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Mon Mar 11 02:54:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690690, encodeId=29ff169069076, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Wed Nov 28 03:54:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407751, encodeId=1f11140e75172, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538784, encodeId=2f581538e84bc, content=<a href='/topic/show?id=93341286ee6' target=_blank style='color:#2F92EE;'>#NLRP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12867, encryptionId=93341286ee6, topicName=NLRP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=981f13051678, createdName=vera_1207, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2018-11-28 bluefate131

    #NLRP3炎症小体#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2030742, encodeId=ac012030e4266, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Mon Mar 11 02:54:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690690, encodeId=29ff169069076, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Wed Nov 28 03:54:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407751, encodeId=1f11140e75172, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538784, encodeId=2f581538e84bc, content=<a href='/topic/show?id=93341286ee6' target=_blank style='color:#2F92EE;'>#NLRP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12867, encryptionId=93341286ee6, topicName=NLRP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=981f13051678, createdName=vera_1207, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2018-11-19 yuandd

    #NLR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2030742, encodeId=ac012030e4266, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Mon Mar 11 02:54:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690690, encodeId=29ff169069076, content=<a href='/topic/show?id=f684128e260' target=_blank style='color:#2F92EE;'>#NLRP3炎症小体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12872, encryptionId=f684128e260, topicName=NLRP3炎症小体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=720529078091, createdName=bluefate131, createdTime=Wed Nov 28 03:54:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407751, encodeId=1f11140e75172, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538784, encodeId=2f581538e84bc, content=<a href='/topic/show?id=93341286ee6' target=_blank style='color:#2F92EE;'>#NLRP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12867, encryptionId=93341286ee6, topicName=NLRP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=981f13051678, createdName=vera_1207, createdTime=Mon Nov 19 11:54:00 CST 2018, time=2018-11-19, status=1, ipAttribution=)]
    2018-11-19 vera_1207

    #NLRP3#

    0

相关资讯

Cell Rep：清华大学石彦课题组发文报道膜电位在NLRP3炎症小体激活过程中的重要意义及相关机制

2018年8月28日，清华大学免疫研究所石彦课题组在《Cell Reports》在线发表题为“A membrane potential and calpain-dependent reversal of Caspase-1 inhibition regulates canonical NLRP3 inflammasome”的研究论文。该论文报道了膜电位在NLRP3炎症小体激活过程中的重要意义及相关

Nat Med：NOX4介导的脂肪酸氧化促进NLRP3炎症小体激活

本研究我们发现NOX4介导脂肪酸氧化促进NLRP3激活。

EMBO Mol Med：曲尼斯特可抑制NLRP3炎症小体相关炎症性疾病

近日，中国科学技术大学生命科学学院、中国科学院天然免疫与慢性疾病重点实验室和合肥微尺度物质科学国家研究中心周荣斌、江维、张华凤和梁高林研究组与厦门大学邓贤明、中国科大附属第一医院陶金辉研究组合作，发现“老药”曲尼斯特（Tranilast）可通过抑制NLRP3炎症小体改善其驱动的相关炎症性疾病。